New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 29, 2012
13:55 EDTBAX, BAX, BAYRY, BAYRY, BIIB, BIIB, PBTH, PBTH, NVO, NVOLeerink's biotech analyst holds an analyst/industry conference call
Biotech Analyst Schimmer discusses the outlook for long-acting factor replacements in hemophilia on an Analyst/Industry conference call. Relevant covered companies BAX, BAYRY, BIIB, PBTH and NVO may be included on the Analyst/Industry conference call to be held on March 29 at 2 pm.
News For BAX;BAYRY;BIIB;PBTH;NVO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
March 2, 2015
07:42 EDTBAXBaxter still undervalued heading into split, says Leerink
Leerink its sum-of-the-parts analysis indicates Baxter shares remain undervalued heading into the company's split. The firm reiterates an Outperform rating on the name with a slightly reduced price target of $82.
February 27, 2015
07:37 EDTBIIBBiogen removed from the short-term buy list at Deutsche Bank
Subscribe for More Information
07:19 EDTBIIBBiogen, Sobi report Phase 3 Alprolix paediatric study meets primary endpoint
Subscribe for More Information
07:10 EDTBIIBBiogen Idec, Swedish Orphan Biovitrum AB announce positive Alprolix results
Subscribe for More Information
February 26, 2015
18:44 EDTNVONovo Nordisk receives Health Canada approval for Saxenda
Subscribe for More Information
11:36 EDTBAYRYBayer sees FY15 sales EUR 46
The company expects positive currency effects on sales of about 3% compared with the previous year. Bayer plans to raise EBITDA before special items by a low- to mid-teens percentage, allowing for expected positive currency effects of about 2 percent. Bayer aims to increase core earnings per share by a low-teens percentage, allowing for expected positive currency effects of around 3%.
11:35 EDTBAYRYBayer reports FY14 net income EUR 3.43B vs. EUR 3.19B last year
Subscribe for More Information
08:15 EDTBIIBBiogen shares likely to continue to advance, says RBC Capital
Subscribe for More Information
06:30 EDTBAYRYBayer says flotation of MaterialScience 'proceeding on schedule'
Subscribe for More Information
February 25, 2015
06:14 EDTBIIBPTC Therapeutics takeout price likely tops $100/share, said Credit Suisse
Credit Suisse yesterday raised its price target for PTC Therapeutics (PTCT) shares to $100 from $66 after Reuters reported the drug market is starting a sale process with Shire (SHPG) and Biomarin (BMRN) as possible suitors. The firm believes a takeout is a likely outcome before or after data the Phase III data expected to be announced in October. PTC has Translarna Phase III trials ongoing in Duchenne muscular dystrophy and cystic fibrosis to support full approval in the U.S. Credit Suisse said yesterday in a note to investors that a takeout value for the company likely exceeds $100 per share. It believes PTC would be a good fit for Vertex (VRTX), Biogen (BIIB), Roche (RHHBY) and others. The firm kept an Outperform rating on the stock. PTC Therapeutics shares closed yesterday up $6.20 to $71.16.
February 23, 2015
09:08 EDTBAXBaxter announces Illinois headquarters for biopharmaceutical spin-off
Subscribe for More Information
February 20, 2015
12:02 EDTNVOEmisphere says Novo Nordisk completes Phase 2 OG217SC trial
Emisphere Technologies (EMIS) highlighted positive Phase 2 data from Eligen licensee Novo Nordisk (NVO) pertaining to OG217SC, the oral formulation of semaglutide, a long-acting human GLP-1 analogue that stimulates insulin and suppresses glucagon secretion in a glucose-dependent manner. OG217SC is provided in a tablet formulation with an absorption-enhancing excipient, SNAC. SNAC is included in the Eligen Carrier Concept. Novo Nordisk announced that it has successfully completed the phase 2 trial for OG217SC, investigating dose range, escalation, efficacy and safety of once-daily oral semaglutide compared with oral placebo or once-weekly subcutaneously administered semaglutide in around 600 people with type 2 diabetes treated for 26 weeks. Results of the study are available on Novo Nordisk's website. Based on these results, Novo Nordisk announced that it will initiate consultations with regulatory authorities subsequent to which a decision of whether to progress OG217SC into phase 3 development will be made. Under its GLP-1 License Agreement, Novo Nordisk is working to develop and commercialize oral formulations of its proprietary GLP-1 receptor agonists in combination with Emisphere carriers. Under the GLP-1 License Agreement, Emisphere could receive additional contingent product development and sales milestone payments and would also be entitled to receive royalties in the event Novo Nordisk commercializes products developed under such Agreement. Under the GLP-1 License Agreement, Novo Nordisk is responsible for the development and commercialization of the products.
07:23 EDTBAYRYAbbVie replaces Pfizer as top global pharma pick at Jefferies
Subscribe for More Information
07:08 EDTBAXAmerican Academy of Allergy, Asthma and Immunology to hold annual meeting
2015 Annual Meeting of AAAAI is being held in Houston, Texas on February 20-24.
06:29 EDTBAYRYBayer close to selling diabetes unit to Panasonic, Bloomberg says
Subscribe for More Information
February 19, 2015
18:25 EDTBIIB, BAYRY, BAXPiper Jaffray biotech analyst to hold analyst/industry conference call
Subscribe for More Information
16:50 EDTBAYRYSanofi appoints Olivier Brandicourt CEO
Subscribe for More Information
14:53 EDTBAYRYBayer near sale of diabetes unit to KKR backed venture, Bloomberg says
Subscribe for More Information
14:08 EDTBIIBBiogen consortium identifies new ALS gene and signaling pathways
Subscribe for More Information
14:01 EDTBAYRYBayer near sale of diabetes unit to KKR's Panasonic Healthcare, Bloomberg says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use